Oncology News | pharmaphorum

News

Gamble by Takeda on unproven cancer mechanism draws a blank

Takeda says a phase 3 trial of its cancer candidate pevonedistat – a class-leading NEDD8-activating enzyme inhibitor – has failed to show a benefit in patients with blood cancers, placing i

News

Incyte, MorphoSys' CAR-T rival tafasitamab approved in EU

Incyte and MorphoSys' antibody therapy tafasitamab has been approved in Europe, promising to provide a more convenient alternative to expensive and cumbersome CAR-T therapies for patients w

News

Novartis' bid to extend Kymriah into earlier use hits a road...

Novartis' CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few years ago, but hasn't added to its label since.

News

Third strike for GSK/Merck as bintrafusp alfa flubs again

GlaxoSmithKline's big gamble on Merck KGaA's bintrafusp alfa has gone from bad to worse, after the drug failed yet another mid-stage trial.

News

Pfizer vaults into CD47 arena, buying Trillium for $2.3 bill...

Pfizer is the latest big pharma company to take a position on drugs that target CD47 – a 'don't eat me' signal that protects cancer cells from being attacked by the immune system.

News

BMS gets FDA nod for Opdivo as first adjuvant bladder cancer...

Bristol Myers Squibb has scored a win in its drive to get Opdivo into earlier lines of cancer therapy, getting FDA approval for the drug for post-surgical treatment of invasive bladder canc

Gamble by Takeda on unproven cancer mechanism draws a blank

Incyte, MorphoSys' CAR-T rival tafasitamab approved in EU

Novartis' bid to extend Kymriah into earlier use hits a road...

Third strike for GSK/Merck as bintrafusp alfa flubs again

Pfizer vaults into CD47 arena, buying Trillium for $2.3 bill...

BMS gets FDA nod for Opdivo as first adjuvant bladder cancer...

Novo Nordisk preps filings for sickle cell drug etavopivat

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks